Nearly Half of U.S. COVID-19 Cases Now Caused by JN.1 Variant
By Physician’s Briefing Staff HealthDay Reporter
THURSDAY, Dec. 28, 2023 -- The JN.1 variant, a descendant of the variant BA.2.86, now accounts for 44 percent of COVID-19 cases, up from roughly 7 percent in late November, the latest data from the U.S. Centers for Disease Control and Prevention show.
The speed at which the JN.1 variant has spread this month suggests it may spread more easily and be better at evading immune systems than other circulating variants, according to a recent CDC report. "It is too early to know whether or to what extent JN.1 will cause an increase in infections or hospitalizations," the CDC said in its report.
Luckily, JN.1 does not seem to be causing more severe illness yet. Additionally, the updated COVID-19 vaccines that were released in September produce antibodies that work against JN.1, which is distantly related to the XBB.1.5 variant the tweaked vaccines target.
Despite the fact that JN.1 may not cause more severe disease than other variants, hospitalizations have started creeping up recently. For the week of Dec. 10, there were just under 26,000 COVID-19-linked hospitalizations, a 10 percent increase from about 23,000 hospitalizations the week before. However, those numbers are still far lower than they were during the peak of the tripledemic last winter, when COVID-19, flu, and respiratory syncytial virus cases all surged simultaneously.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Further Support and Information on COVID-19
Read this next
Higher COVID-19 Vaccination Rates Tied to Decrease in Childhood Asthma Symptoms
WEDNESDAY, July 3, 2024 -- Higher COVID-19 vaccination rates are associated with a lower prevalence of parent-reported childhood asthma symptoms, according to a research letter...
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.